Retension Pharmaceuticals (NASDAQ:RTSN) Announces Quarterly Earnings Results

Retension Pharmaceuticals (NASDAQ:RTSN – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($7.33) EPS for the quarter, Zacks reports.

Retension Pharmaceuticals Stock Up 6.5%

RTSN traded up $0.74 on Wednesday, hitting $12.15. 32,365 shares of the company’s stock were exchanged, compared to its average volume of 121,834. Retension Pharmaceuticals has a fifty-two week low of $9.66 and a fifty-two week high of $18.64.

Analyst Ratings Changes

RTSN has been the topic of a number of recent analyst reports. Guggenheim initiated coverage on Retension Pharmaceuticals in a research report on Monday, November 2nd. They set a “buy” rating and a $55.00 target price on the stock. Zacks Research assumed coverage on shares of Retension Pharmaceuticals in a research report on Wednesday, November 4th. They set a “hold” rating for the company. Leerink Partners started coverage on shares of Retension Pharmaceuticals in a report on Tuesday, November 3rd. They set a “strong-buy” rating on the stock. Oppenheimer initiated coverage on shares of Retension Pharmaceuticals in a research note on Tuesday, November 3rd. They set an “outperform” rating and a $50.00 target price for the company. Finally, Wall Street Zen upgraded shares of Retension Pharmaceuticals to a “hold” rating in a research report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $52.50.

Get Our Latest Research Report on Retension Pharmaceuticals

Insider Activity

In other Retension Pharmaceuticals news, CEO Eric L. Keller acquired 20,800 shares of the company’s stock in a transaction that occurred on Tuesday, October 13th. The stock was bought at an average price of $12.00 per share, with a total value of $249,600.00. Following the purchase, the chief executive officer owned 423,377 shares in the company, valued at approximately $5,080,524. The trade was a 5.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Franklin M. Berger acquired 10,000 shares of the business’s stock in a transaction on Tuesday, October 13th. The stock was acquired at an average price of $12.00 per share, with a total value of $120,000.00. Following the acquisition, the director owned 10,000 shares in the company, valued at $120,000. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information.

Retension Pharmaceuticals Company Profile

(Get Free Report)

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.

See Also

Receive News & Ratings for Retension Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retension Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.